Ingenia Therapeutics is pursuing a KOSDAQ listing with its proprietary bispecific antibody platform 'LCIDEC' as its core competitive edge. Biotech investors are paying close attention to the company's drug development capabilities for vascular diseases and the expandability of its pipeline.

■ IPO Subscription Schedule and Offering Price According to the financial investment industry, Ingenia Therapeutics plans to conduct its public offering subscription for general investors from July 30 to 31. The indicative offering price range is set at 12,000 to 14,500 won, with Samsung Securities serving as the lead underwriter. The final offering price and the results of the institutional bookbuilding will be determined later. However, the scheduled dates are subject to change.

■ LCIDEC Platform: A Differentiated Approach to Vascular Diseases Ingenia Therapeutics' core technology is its proprietary LCIDEC (Ligand Capture Internalization Degradation in Endothelial Cells) platform. This platform utilizes the TIE2 receptor found in vascular endothelial cells to normalize vascular function, rapidly drawing disease-causing proteins from the blood into the cells for degradation. The company is developing bispecific antibodies that combine an antibody or protein fragment—capable of recognizing disease-causing target proteins—with a TIE2 antibody. By efficiently capturing target proteins and transporting them into cells for degradation, the company aims to differentiate itself from existing therapeutic strategies. The company explained that through proof-of-concept studies, it confirmed that the bispecific antibodies under development can rapidly internalize and degrade disease-related proteins. Based on this, the company expects to eliminate disease-causing factors in the body more quickly, thereby enhancing therapeutic efficacy and clinical efficiency.

■ Pipeline Diversification and Global Expansion The LCIDEC platform is also highly regarded for its potential to expand its application beyond specific diseases to a wide range of vascular-related conditions. Leveraging this platform, Ingenia Therapeutics is developing multiple new drug candidates to diversify its pipeline. The company's lead pipeline asset, IGT-427, is reportedly currently in Phase 3 clinical trials conducted by the global pharmaceutical company MSD. The company's strategy is to use this as a starting point to further expand the scalability of its platform technology and explore global technology commercialization opportunities. Recently, the biotech industry has seen a growing interest in platform-based drug discovery companies. The industry is closely watching how much Ingenia Therapeutics will be able to expand its research and development capabilities post-IPO, backed by its proprietary technology and competitive pipeline.

[This article was written with the assistance of AI. AI was utilized in the writing process, and the final content was reviewed for factual accuracy. This article does not constitute an investment solicitation for any specific public offering, and the responsibility for investment decisions lies solely with the investor.]